RESUMEN
The NCCN Guidelines for Colorectal Cancer (CRC) Screening outline various screening modalities as well as recommended screening strategies for individuals at average or increased-risk of developing sporadic CRC. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize 2018 updates to the NCCN Guidelines, with a primary focus on modalities used to screen individuals at average-risk for CRC.
Asunto(s)
Neoplasias Colorrectales/diagnóstico , Detección Precoz del Cáncer/estadística & datos numéricos , Tamizaje Masivo/normas , Oncología Médica/normas , Factores de Edad , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/sangre , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/aislamiento & purificación , Colonoscopía/métodos , Colonoscopía/normas , Neoplasias Colorrectales/sangre , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/patología , ADN de Neoplasias/genética , ADN de Neoplasias/aislamiento & purificación , Detección Precoz del Cáncer/métodos , Heces/química , Humanos , Inmunoquímica/métodos , Inmunoquímica/normas , Tamizaje Masivo/métodos , Oncología Médica/métodos , Persona de Mediana Edad , Sangre Oculta , Ensayos Clínicos Controlados Aleatorios como Asunto , Septinas/genética , Sociedades Médicas/normas , Factores de Tiempo , Tomografía Computarizada por Rayos X/métodos , Tomografía Computarizada por Rayos X/normas , Estados UnidosRESUMEN
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal provide recommendations for the management of patients with high-risk syndromes associated with an increased risk of colorectal cancer (CRC). The NCCN Panel for Genetic/Familial High-Risk Assessment: Colorectal meets at least annually to assess comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. These NCCN Guidelines Insights focus on genes newly associated with CRC risk on multigene panels, the associated evidence, and currently recommended management strategies.